Evidence map›Paper›PMID 29326937›Full record

ArticleFrontiers in medicine2017

Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.

Kathleen S Garland, Stéphanie E Reitsma, Toshiaki Shirai, Jevgenia Zilberman-Rudenko, Erik I Tucker, David Gailani, András Gruber, Owen J T McCarty, Cristina Puy

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Mechanisms of ADAMTS13 regulation.Journal of thrombosis and haemostasis : JTH · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kathleen S GarlandDivision of Pediatric Hematology/Oncology, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Stéphanie E ReitsmaDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Toshiaki ShiraiDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Jevgenia Zilberman-RudenkoDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Erik I TuckerDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
David GailaniVanderbilt University School of Medicine, Nashville, TN, United States.
András GruberDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Owen J T McCartyDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Cristina PuyDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Oregon Health & Science University · USAronora (United States) · USVanderbilt University · US

Funding

Oregon Clinical and Translational Research InstituteUL1TR000128 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$28.7M
Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
Biochemistry and Pathophysiology of Factor XI and Contact ActivationR35HL140025 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAILANI, DAVID · 2018 to 2024
$5.5M
Factor XI inhibitor for thrombosisR44HL106919 · NHLBI · ARONORA, INC. · PI LORENTZ, CHRISTINA U, TUCKER, ERIK IAN · 2012 to 2019
$5.0M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
Role of FXI in Thrombohemorrhagic ComplicationsF31HL136230 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ZILBERMAN-RUDENKO, JEVGENIA · 2017 to 2020
$161k
NCATS NIH HHS UL1 TR000128NHLBI NIH HHS F31 HL136230NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R44 HL106919NIGMS NIH HHS R01 GM116184
6 · The paper itself

Abstract

Platelet recruitment to sites of vascular injury is mediated by von Willebrand factor (VWF). The shear-induced unraveling of ultra-large VWF multimers causes the formation of a "stringlike" conformation, which rapidly recruits platelets from the bloodstream. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) regulates this process by cleaving VWF to prevent aberrant platelet adhesion; it is unclear whether the activity of ADAMTS13 itself is regulated. The serine proteases α-thrombin and plasmin have been shown to cleave ADAMTS13. Based on sequence homology, we hypothesized that activated coagulation factor XI (FXIa) would likewise cleave ADAMTS13. Our results show that FXIa cleaves ADAMTS13 at the C-terminal domains, generating a truncated ADAMTS13 with a deletion of part of the thrombospondin type-1 domain and the CUB1-2 domains, while α-thrombin cleaves ADAMTS13 near the CUB1-2 domains and plasmin cleaves ADAMTS13 at the metalloprotease domain and at the C-terminal domain. Using a cell surface immunoassay, we observed that FXIa induced the deletion of the CUB1-2 domains from ADAMTS13 on the surface of endothelial cells. Removal of the C-terminal domain of ADAMTS13 by FXIa or α-thrombin caused an increase in ADAMTS13 activity as measured by a fluorogenic substrate (FRETS) and blocked the ability of ADAMTS13 to cleave VWF on the endothelial cell surface, resulting in persistence of VWF strands and causing an increase in platelet adhesion under flow conditions. We have demonstrated a novel mechanism for coagulation proteinases including FXIa in regulating ADAMTS13 activity and function. This may represent an additional hemostatic function by which FXIa promotes local platelet deposition at sites of vessel injury.

Indexed as

a disintegrin and metalloproteinase with a thrombospondin type 1 motifcoagulationfactor XImember 13plateletsvon Willebrand factor

Identifiers

PMID29326937
PMCPMC5742325
OpenAlexW2776355388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.